The Scottish Medicines Consortium accepts the use of Adtralza®▼(tralokinumab) for adult patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy
The Scottish Medicines Consortium (SMC) has issued advice accepting tralokinumab for use within NHS Scotland for the treatment of moderate-to-severe atopic derm... Read More...